Aldona Staar Kumosa, MD
Internal Medicine · Parker, CONPI 1447342043
Payments from drug & device makers
Across 282 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$664
- AstraZeneca$616
- Novo Nordisk$496
- Amgen$383
- Astellas Pharma US Inc$375
- AbbVie$269
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,70696%
- Education$1944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 52 | $664 |
| AstraZeneca | 38 | $616 |
| Novo Nordisk | 26 | $496 |
| Amgen(2 entities) | 22 | $383 |
| Astellas Pharma US Inc | 10 | $375 |
| AbbVie(2 entities) | 14 | $269 |
| Lilly USA, LLC | 16 | $225 |
| Novartis | 10 | $198 |
| Johnson & Johnson | 11 | $179 |
| Exact Sciences | 8 | $178 |
| Abbott | 7 | $143 |
| GSK | 7 | $115 |
| Amarin Pharma, Inc. | 6 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| Bristol Myers Squibb | 4 | $92 |
| Bayer | 4 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Sunovion Pharmaceuticals Inc. | 4 | $67 |
| Merck | 4 | $58 |
| Boehringer Ingelheim | 3 | $48 |
| Therapeuticsmd, Inc. | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Edwards Lifesciences | 1 | $26 |
| Sanofi | 1 | $25 |
| Almatica Pharma LLC | 1 | $24 |
| Shire North American Group Inc | 1 | $20 |
| Cranial Technologies, Inc | 1 | $18 |
| GE HealthCare | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$4,900 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 154 | $166,712 |
| OzempicSemaglutide | 77 | $92,612 |
| MyrbetriqMirabegron | 52 | $49,686 |
| XareltoRivaroxaban | 29 | $41,570 |
| MounjaroTirzepatide | 30 | $35,094 |
| JardianceEmpagliflozin | 26 | $34,855 |
| JanuviaSitagliptin Phosphate | 20 | $33,491 |
| FarxigaDapagliflozin Propanediol | 15 | $25,292 |
| GemtesaVibegron | 29 | $24,337 |
| VivitrolNaltrexone Microspheres | 11 | $17,760 |
| TrulicityDulaglutide | 12 | $17,430 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $15,927 |
| SynthroidLevothyroxine Sodium | 106 | $9,584 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $8,417 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $664 | $173,641168 claims |
| Novo NordiskOzempic | $496 | $92,61277 claims |
| Lilly USA, LLCMounjaro, Trulicity | $225 | $52,52442 claims |
| Astellas Pharma US IncMyrbetriq | $375 | $49,68652 claims |
| Johnson & JohnsonXarelto | $179 | $41,57029 claims |
| MerckJanuvia, Janumet | $58 | $39,87931 claims |
| Boehringer IngelheimJardiance | $48 | $34,85526 claims |
| AstraZenecaFarxiga, Symbicort | $616 | $33,70931 claims |
| GSKBreo Ellipta | $115 | $15,92728 claims |
| AbbVieSynthroid | $269 | $9,584106 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $2,003180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Parker
- Kathryn PolovitzParker$403K
- Beatriz LinnParker$9K
- Stanton ElziWheat Ridge$9.2M
- Jason HenryDenver$7.3M
- Kenneth CohenLakewood$4.5M
- Luke WebbColorado Springs$2.1M
- Alexis LealAurora$2M
- Mauricio WaintrubAurora$1.3M
- Steven BrodieColorado Springs$883K
- Monica GrafalsAvon$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.